2025年暴跌50%!诺和诺德遭遇史上最差一年,“减肥药狂潮”仿佛从未发生

华尔街见闻
Dec 11

诺和诺德曾因减肥药Wegovy的成功而一度成为欧洲市值最高的上市公司,如今,却因临床试验结果不佳、多次盈利预警以及市场竞争激烈,遭遇有史以来表现最差一年。今年以来,诺和诺德股价暴跌逾50%,且几乎抹去了自2021年Wegovy获批用于减肥治疗以来的惊人涨幅。投资者担心,随着司美格鲁肽(Wegovy和Ozempic的关键成分)主要化合物专利将于2032年在美国到期,公司未来销售增长的来源面临不确定性...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10